Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07030894 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nefecon and Ambrisentan in IgA Nephropathy

Name: Nefecon and Ambrisentan in IgA Nephropathy — clinical trial record (NCT07030894)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BAIN

StatusRecruiting

PhasePhase 4

SponsorThe First Hospital of Jilin University

Started2025-09-01

View on ClinicalTrials.gov ↗

Amendment history

2025-09-09

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2

Trial statusNot Yet Recruiting→Recruiting

Study sites0→1

2025-08-28

Study Status v1

Start date2025-06-10→2025-09-01

2025-06-20

Original filing

The First Hospital of Jilin University

86 trials monitored

See 2 trials at risk

Chronic Kidney Disease

1,314 trials monitored

See 54 trials at risk

Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g/24h), observing the degree and safety of reducing urinary protein and delaying eGFR progression, and observing changes in serum Gd-IgA1 levels

Trial Details

NCT Number	NCT07030894
Lead Sponsor	The First Hospital of Jilin University
Conditions	IgA Nephropathy, Chronic Kidney Disease, Proteinuria
Enrollment	129 participants
Start Date	2025-09-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-15